Internalisation of isotope-coupled somatostatin analogues

With the technique of in vivo somatostatin (SRIF) receptor (sst) scintigraphy a variety of human sat-positive tumours can be visualised 24-48 h after intravenous injection of the radiolabelled (SRIF) analogue [In-111-DTPA-D-Phe(1)]octreotide. This rather long residence time of radioactivity on tumours suggests that the radioligand is internalised by the tumour cells; literature data for normal pituitary and pancreatic islet cells agree with this. Internalised SRIF has been found to be associated with cytoplasmic organelles, especially the Golgi apparatus, lysosomes and secretory granules. We have found that mouse AtT20 and primary cultures of human growth-hormone-secreting pituitary adenoma cells internalised a high amount of radio-iodinated [Tyr(3)]octreotide. Since octreotide binds with high affinity to the sst(2). and sst(5) subtypes and because both sat subtypes are expressed in these cells, one or both subtypes may be involved in this process. We also found that unlabelled octreotide, SRIF-14 or SRIF-28 can increase the internalisation of the radioligand. These observations, together with other studies on the manipulation of sst expression, may help to optimise the uptake of radioligand in in vivo sst scintigraphy in humans and improve the potential effect of radiotherapy with radiolabelled (subtype-specific) SRIF analogues.